| Identification | More | [Name]
Doxifluridine | [CAS]
3094-09-5 | [Synonyms]
5'-DEOXY-5-FLUOROURIDINE
5'-DEOXYFLUOROURIDINE
5'-DFUR
5'DFURD
(+)-5-FLUORO-5'-DEOXYURIDINE
5-FLUORO-5'-DEOXYURIDINE
DOXIFLURIDINE
RO-21-9738
5’-deoxy-5-fluoro-uridin
flutron
furtulon
Doxifluridine (furtulon)
DOXIFLUIRDINE
5'-Deoxy-fluorouridine(DFUR)/Doxifluridine
(+)-5-FLUORO-5'-DEOXYURIDINE 97%
5-FLURO-5’-DEOXYURIDINE
5Urd, 5-Fluoro-5deoxyuridine
5Deoxy-5-fluorouridine, 5DFUR, 5dFUrd, Ro-21-9738
Doxifluidine
DOXIFLURIDINE(SUBJECTTOPATENTFREE) | [EINECS(EC#)]
221-440-1 | [Molecular Formula]
C9H11FN2O5 | [MDL Number]
MFCD00866530 | [Molecular Weight]
246.19 | [MOL File]
3094-09-5.mol |
| Chemical Properties | Back Directory | [Appearance]
White Solid | [Melting point ]
188-192 °C(lit.)
| [alpha ]
D25 +18.4° (c = 0.419 in water) | [density ]
1.3751 (estimate) | [refractive index ]
20 ° (C=1, H2O) | [storage temp. ]
Inert atmosphere,Room Temperature | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
7.4(at 25℃) | [color ]
White | [Usage]
An antitumor agent efficient in tumors, cell lines or in fibroblasts tranformed by H-ras or trk oncogenes. A metabolite of Capecitabine | [Merck ]
3437 | [Major Application]
pharmaceutical small molecule | [InChI]
InChI=1S/C9H11FN2O5/c1-3-5(13)6(14)8(17-3)12-2-4(10)7(15)11-9(12)16/h2-3,5-6,8,13-14H,1H3,(H,11,15,16)/t3-,5-,6-,8-/m1/s1 | [InChIKey]
ZWAOHEXOSAUJHY-ZIYNGMLESA-N | [SMILES]
C[C@H]1O[C@@H](N2C=C(F)C(=O)NC2=O)[C@H](O)[C@@H]1O | [CAS DataBase Reference]
3094-09-5(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing . | [WGK Germany ]
2
| [RTECS ]
YU7526000
| [Hazard Note ]
Irritant | [HazardClass ]
IRRITANT, IRRITANT-HARMFUL | [HS Code ]
29349990 | [Storage Class]
11 - Combustible Solids | [Toxicity]
LD50 (14 day) in mice or rats (mg/kg): >1000 i.v.: >2000 s.c.; in male, female mice, male, female rats (mg/kg): >5000, >5000, 3471, 3390 orally (Shimizu) |
| Hazard Information | Back Directory | [Description]
Doxifluridine is a prodrug derivative of 5-fluorouracil (5-FU). As an antineoplastic it is
more potent than 5-FU in the treatment of breast, stomach, colon and rectal cancers. | [Chemical Properties]
White Solid | [Originator]
Hoffmann-LaRoche (USA) | [Uses]
5’-Deoxy-5-fluorouridine is a metabolite of the chemotherapeutic agent Capecitabine (C175650). 5’-Deoxy-5-fluorouridine is an antitumor agent efficient in tumors, cell lines or in fibroblasts tranformed by H-ras or trk oncogenes. | [Uses]
A prodrug of 5-Flurouridine. A fluorinated pyrimidine nucleoside with cytostatic activity | [Uses]
An antitumor agent efficient in tumors, cell lines or in fibroblasts tranformed by H-ras or trk oncogenes. A metabolite of Capecitabine | [Uses]
antineoplastic, pyrimidine antimetabolite | [Definition]
ChEBI: A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluoro
racil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase. | [Brand name]
Furtulon | [Biochem/physiol Actions]
Doxifluridine is an antitumor agent efficient in tumors, cell lines or in fibroblasts transformed by H-ras or trk oncogenes. Possesses anticachectic activity which is independent of its antiproliferative activity. |
|
| Company Name: |
J & K SCIENTIFIC LTD.
|
| Telephone: |
18210857532 18210857532 |
| Website: |
https://www.jkchemical.com |
| Company Name: |
Energy Chemical
|
| Telephone: |
400-0056266 |
| Website: |
www.energy-chemical.com |
| Company Name: |
China Langchem Inc.
|
| Telephone: |
0086-21-58956006 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList19141/0_EN.htm |
|